HELSINKI, June 1, 2010 /PRNewswire/ — MediSapiens,
world’s first software company for personalized cancer medicine in
oncology clinics and drug development, completed $ 1 million (EUR 0.8
million) seed round investment from Veraventure, ETFIII
advised by Eqvitec Partners, VTT Ventures and Lifeline
Ventures.
MediSapiens is based on scientific research at the VTT Technical
Research Centre of Finland and its
collaborators. MediSapiens hosts world’s largest unified gene
expression database of human tissues and diseases. This enables
scientists to understand the role of human genes in health and
disease – to be applied in helping oncologists in choosing optimal
treatments and biopharmaceutical companies in developing next
generation personalized medicines.
“The latest research – such as The Cancer Genome Atlas funded by
the NIH – demonstrates that every patient’s cancer is a complex,
unique combination of genetic mutations and abnormally expressed
genes. The MediSapiens software gives personalized and clinically
applicable insight into each patient’s cancer,” says Tommi Pisto, CEO and Co-founder of
MediSapiens.
“Making use of the data produced by the global scientific
community provides a new and significant opportunity to understand
cancer. Oncologists can benefit when these reference datasets are
used to interpret molecular profiling results for individual
patients,” comments Professor Olli
Kallioniemi, MediSapiens board member and director of the
Institute for Molecular Medicine Finland (FIMM).
About MediSapiens
MediSapiens, the world’s firs
‘/>”/>
